Welcome to the latest edition of the BioLines Weekender. 

Once again the BioNJ Team is on the move with a number of exciting activities to report on. In addition to attending the royal wedding and the final Chelsea vs. Manchester United football game at Wembley Stadium, we...
  • Participated in Students 2 Science and New Jersey Innovation Institute Board Meetings 
  • Co-hosted a Congressional Staff Briefing on emergency preparedness
  • Attended Princeton Innovation Center BioLabs' Ribbon Cutting Ceremony
  • Met with Asm. Andrew Zwicker, Asm. Dan Benson, Asw. Annette Quijano, and Asm. Christopher DePhillips
  • Attended Union County and Somerset County ELC meetings with Melanie Willoughby, Director, NJ Business Action Center and Sen. Michael Doherty
  • Held a call with the newly established HR Leadership Network
  • Hosted BioNJ's Finance Forum focused on tax reform, the NOL Program and cyber security
  • Began planning for BIO 2019 returning to Philadelphia next yearI
Have a safe holiday weekend as we remember and honor those who have risked their lives to protect our country. Thank you to our brave service men and women.

Because Patients Can't Wait®,
The BioNJ Team


Job Opportunities at BioNJ



BioNJ, the trade association for the biotechnology industry in New Jersey, seeks an experienced State and federal government relations professional to join its Team. Reporting directly to the President and CEO, this individual will develop and execute government relations strategy at the State and federal levels.

Leveraging and building on the current BioNJ reputation, the Vice President of State and Federal Government Relations will lead the development of specific strategic initiatives to support the legislative and regulatory priorities of the association and the industry. This individual will be responsible for advancing these initiatives and working with the Public Policy Committee and the BioNJ Team to ensure that these initiatives are advanced and that public policy priorities are achieved.

For more information or to be considered for this position, please submit cover letter, resume, and salary requirements to [email protected].

BioNJ Calendar

Clinical Trials Supply Chain in Transition
NJIT Campus, Newark, NJ

June 19, 2018
BioNJ's 6th Annual HR Conference 
Institute for Life Science Entrepreneurship/Kean University, Union, NJ

June 22, 2018
Beyond Value Frameworks: Defining the Value of Medical Innovation Workshop
Amicus Therapeutics, Cranbury, NJ

October 11, 2018
Save the date!
BioNJ's C-Suite Summit
Bridgewater Marriott, Bridgewater, NJ

October 25, 2018

Putting Patients First: The Value of Medical Innovation
Brought to You by Celgene Corporation

Medical innovation enables longer and better quality lives and, in turn, reduces the costs of healthcare. Share with our community how your medical innovation is improving lives and impacting healthcare costs. Send us your Patient and related stories to [email protected]. Plus, click here for valuable tools and resources on the Value of Medical Innovation.



A ribbon-cutting, speeches and tour of its extensive laboratory space marked the formal opening of the new high-tech Princeton Innovation Center BioLabs incubator. A crowd of more than 100 representatives from Princeton University, the town of Plainsboro, local industries and the center's first tenant companies attended the event at the Forrestal Center in Plainsboro. Princeton Innovation Center BioLabs offers co-working lab and office space for high-tech startup companies formed by Princeton University faculty, students and alumni as well as members of the wider New Jersey community.



The Board of the New Jersey Economic Development Authority (EDA) approved two actions to help nurture the growth of the State's innovation economy. Echoing the priorities set by Governor Murphy, the Board authorized an agreement with the New Brunswick Development Corporation (DEVCO) to advance development of "The Hub" in downtown New Brunswick, and a venture fund investment that will support growth-stage, software and technology-enabled companies in New Jersey.



Morristown Medical Center , a part of Atlantic Health System, has launched the Center for Nursing Innovation, an internal incubator in which the hospital's nearly 1,600 nurses can develop ideas for new medical products.



The New Jersey Innovation Institute (NJII), an NJIT Corporation, and Somerville-based HealRWorld (HRW) have partnered to form a New Jersey-based accelerator. HealRWorld CEO Michele Bongiovanni stated, "HRW is proud to partner with NJII in the new global accelerator and offer a three pronged value proposition: access to sustainability innovation for the corporations, for small innovative companies real world challenges, coaching and funding, and curated deal flow to investors."



Most people have never heard of Behçet's disease a painful, chronic condition that causes sores in the mouth and elsewhere on the body. Since only 16,000 to 20,000 people in the United States are affected by this condition, that's hardly surprising. But for those suffering in silence, it's important to know that, while there is no cure, diagnosis and treatment can help manage symptoms. 



While some brides-to-be spend the week before their big day worrying about the weather or fitting into their dress, Danielle Kroft was dealing with a flare-up of her ulcerative colitis (UC). And a wedding dress wasn't exactly going to make the situation easier.  This is what life is like for more than 900,000 people in the United States living with UC, an unpredictable inflammatory bowel disease (IBD) with symptoms that come and go over time. Some patients go years without symptoms; others have frequent flare-ups. In a survey, almost two-thirds of patients feel like UC controls their lives.



Scientists, physicians and patient advocates gathered in Chicago for the 2018 American Society of Gene & Cell Therapy (ASGCT) annual meeting to discuss results of recent trials for cellular immunotherapies, including c himeric antigen receptor (CAR) T cell therapies. These treatments have the potential to change the treatment paradigm in oncology, but obstacles remain for cancer centers seeking to take advantage of this new approach.

BioNJ in the News


Op-ed featured in ROI-NJ

Unfortunately, the barriers patients face in obtaining personalized medicine are being undercut by the way medicines are covered and paid for. Currently, entities called pharmacy benefit managers, or PBMs, administer prescription drug benefits for the 85 percent of all Americans whose medicines are covered through health plans. And, in an effort to maximize the use of medicines that cost the least or generate the most rebates, PBMs are imposing high out-of-pocket costs, prior authorization and step therapy on the sickest patients with the most complex diseases. As a result, in far too many cases, the health of patients is at risk and health care costs are higher.



Whatever your services needs may be,  BioNJ's Member Service Provider Directory    can guide you to the right source. This Member-only categorical listing by service sector is your "one-stop-shop" solution to support and drive your business.  Click on the RESOURCES tab at www.BioNJ.org to view the full BioNJ Member Service Provider Directory categories. Here's a sample for Contract Research Organizations & Consulting Services providers:                   



NJ Company News

Ever proud of our ecosystem, we are pleased to share our New Jersey Company News. Be sure to click on the article titles below to read the full release.


Princeton -based BioNJ Member  Evotec and Summit-based BioNJ Member Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Evotec has built one of the industry's broadest and most innovative pre-clinical discovery and development platforms. This includes in particular an industry-leading phenotypic screening platform with unique compound libraries and associated target deconvolution capabilities. The collaboration intends to leverage these capabilities with an initial focus on solid tumors.







Morris Plains-based BioNJ Member Immunomedics, Inc. announced that sacituzumab govitecan, its lead investigational ADC, induced promising objective responses as a single agent in heavily pre-treated patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).



Berkeley Heights-based BioNJ Member  Chugai Pharmaceutical Co., Ltd.  announced that it has launched its anti-coagulation factor IXa/X humanized bispecific monoclonal antibody / coagulation factor VIII substitute, (brand name, "HEMLIBRA ®  Subcutaneous Injection 30 mg, 60 mg, 90 mg, 105 mg, 150 mg;" hereafter, "HEMLIBRA") for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors. 




Cranbury-based BioNJ Member  Oncobiologics, Inc.  announced that on  May 11, 2018 , it entered into a purchase agreement with  GMS Tenshi Holdings Pte. Limited  ("GMS Tenshi"), the Company's strategic business partner and largest investor, providing for the private placement of  $15.0 million  of shares of its common stock and warrants that have an aggregate exercise price of approximately  $20.0 million . 



Bridgewater-based BioNJ Member  Eli Lilly and Company  announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. A statistically significantly greater percentage of patients treated with galcanezumab also achieved at least a 50 percent reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint.



Bridgewater-based BioNJ Member  Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved a label update for Taltz® (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Taltz is the first and only treatment approved by the FDA for moderate-to-severe plaque psoriasis that includes such data in its label.



Bridgewater-based BioNJ Member  Eli Lilly and Company  announced an agreement to acquire  AurKa Pharma, Inc. , a company established by TVM Capital Life Science to develop
oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma is studying in Phase 1 clinical trials in multiple types of solid tumors.





Englewood Cliffs-based BioNJ Member  Immune Pharmaceuticals, Inc.  announced that updated data from its Phase 2 study of bertilimumab in patients with moderate-to-extensive bullous pemphigoid (BP) (study  NCT02226146 ) were presented at the  2018 Pre-IID Pemphigus and Pemphigoid Symposium . These updated results include complete follow-up on all subjects enrolled in the study. 



BioNJ Member Pfizer Inc., with offices in Madison, announced that tafamidis received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with transthyretin cardiomyopathy, a rare, fatal, and underdiagnosed condition associated with progressive heart failure. This decision is supported by topline results from the tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, in which tafamidis demonstrated a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations.



BioNJ Member Pfizer Inc., with offices in Madison, announced that results from a study analyzing real-world effectiveness data found that Prevnar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 Protein]) reduced the risk of hospitalization from vaccine-type pneumococcal community-acquired pneumonia (CAP) by 73% (95% CI: 12.8−91.5%) in adults aged 65 and older. Importantly, Prevnar 13 (PCV13) worked under real-world conditions where people received pneumococcal vaccination as advised by their healthcare providers, and many had underlying medical conditions that increase the risk for pneumococcal pneumonia. 



BioNJ Member Pfizer Inc., with offices in Madison, announced positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age. Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. 



BioNJ Member Pfizer Inc., with offices in Madison, announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults. The highest risk of severe outcome from RSV occurs in the first months of life.



Spark Therapeutics and BioNJ Member Pfizer, with offices in Madison, announced that, with a cumulative follow-up of more than 18 patient years of observation (5 to 121 weeks), all 15 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for severe or moderately severe (FIX:C < 2 percent) hemophilia B, had discontinued routine infusions of factor IX concentrates. None of the 15 participants experienced serious adverse events, and there were no thrombotic events or factor IX inhibitors, as of the May 7, 2018 data cutoff. 






Kenilworth -based BioNJ Member  Merck & Co. announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC), met the dual primary endpoints of overall survival (OS) and progression-free survival (PFS). 



Plainsboro-based BioNJ Member Novo Nordisk announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an exclusive collaboration with the University of California San Francisco (UCSF) in which a first milestone in the development of human embryonic stem cell lines has been reached.



Plainsboro-based BioNJ Member Novo Nordisk announced adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed a longer half-life for Refixia®.



The U.S. Food and Drug Administration (FDA) has accepted Bridgewater-based BioNJ Member Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. Developed in partnership with Lexicon Pharmaceuticals, Inc., Zynquista is an investigational oral dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys absorb and eliminate sugar (glucose) resulting in improved glucose control and additional clinical benefits.



Bridgewater-based BioNJ Member Sanofi announced a pivotal Phase 3 trial evaluating Dupixent ®  (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints. In the trial, treatment with Dupixent as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, and certain health-related quality of life measures. Dupixent is the first and only biologic to show positive results in this patient population.





Parsipanny-based Cornerstone Search Group (Cornerstone), a life sciences executive search specialty firm, today announces it has been named one of the 2018 " America's Best Executive Recruiting Firms" by Forbes, for the second year in a row. Cornerstone's unique position as a firm dedicated exclusively to servicing the pharma/biotech industry helped the company rise a remarkable 113 spots from #200 in 2017, to break into the top 100 in less than a year, placing #86 out of over 14,000 nominated firms.



A quest for an optimal location for development of drug-delivery technologies for people suffering from rare and orphan diseases brought Grace Therapeutics to the New Jersey Economic Development Authority's (EDA's) Commercialization Center for Innovative Technologies (CCIT) in 2014. Co-founders George Kottayil and Vimal Kavuru have experience launching, growing and successfully exiting multi-million-dollar pharmaceutical companies. With that strategic insight, the entrepreneurs were first attracted to CCIT, New Jersey's leading life sciences incubator, for several reasons, including its quick application-to-move-in time and its ready-to-use lab space. 



Basking Ridge-based Daiichi Sankyo announced that it has launched in Japan an injection for cancer pain treatment: NaruveinⓇ Injection 2 mg * 20 mg.  Joining the currently marketed extended-release formulation, NarususⓇ Tablets, and immediate-release formulation, NarurapidⓇ Tablets, the injection formulation, NaruveinⓇ Injection, is a new addition to Daiichi Sankyo's analgesic line-up to help meet the diverse needs of patients and health care professionals in Japan.



Basking Ridge-based Daiichi Sankyo and  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement.  Under the terms of the second agreement, Daiichi Sankyo will acquire licenses to Zymeworks' Azymetric™ and EFECT™ technology platforms to develop two additional bispecific antibody therapeutics.



Mahwah-based Glenmark Pharmaceuticals announced that the company has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its leading respiratory pipeline candidate Ryaltris™, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older. 



Mahwah-based Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Colesevelam Hydrochloride Tablets, 625 mg, the generic version of Welchol® 1 Tablets, 625 mg, of Daiichi Sankyo Inc. The company has already commenced supplies of the product to the U.S. market.



Parsippany-based Castle Creek Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of patients with epidermolysis bullosa simplex (EBS), a subtype of EB.



Angel Medical Systems recently announced its FDA approval for the world's first implantable heart monitor that can alert patients before they experience a heart attack.  The Tinton Falls-based company is now preparing for commercialization, after 15 years of working on the device. That includes expanding office space, hiring to increase the current team of 15 and restarting manufacturing -- all with the anticipation of having the device ready to be used by patients in early 2019.



Bellerophon Therapeutics, Inc., with offices in Warren,  announced an agreement with the FDA for the design of its Phase IIb trial evaluating pulsed inhaled nitric oxide (iNO) with its lead candidate INOpulse in patients with pulmonary hypertension associated chronic obstructive pulmonary disease (PH-COPD). The proposed study follows positive Phase IIa data with the treatment, showing improvements in both hemodynamic measures and 6 minute walk distance (6MWD), which is the agreed-upon primary endpoint for the planned 90-patient Phase IIb study.



Teva Pharmaceutical Industries Ltd ., with offices in Fairfield,  announced the publication of data from the Phase III HALO study evaluating the efficacy, safety and tolerability of both quarterly (every three months) and monthly subcutaneous dosing regimens of fremanezumab for the prevention of episodic migraine (EM).  Fremanezumab is a monoclonal antibody that selectively targets CGRP (calcitonin gene-related peptide), a neuropeptide involved in the pathophysiology of migraine. 



Bridgewater-based Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, announced it has received final U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Welchol® (colesevelam HCI) tablets, 625 mg. Amneal has immediately initiated commercialization activities for this first-to-market opportunity.



Bayer, with offices in Whippany, announced that Eylea (aflibercept solution for injection into the eye) has been approved by the Chinese regulatory authorities for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration (wAMD). This is the second indication for Eylea to be approved in China following its recent decision to approve the drug for treatment of visual impairment due to diabetic macular edema.



Oldwick-based  Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today that it has entered into agreements with MacroGenics, Inc. involving two clinical-stage assets. Provention has acquired all rights to teplizumab to be further developed as PRV-031 and licensing rights to MGD010 for development as PRV-3279.



Woodcliff Lake-based Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Eagle's ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.



Parsippany-based  Zoetis Inc . and Abaxis, Inc. announced a definitive merger agreement pursuant to which Zoetis will acquire Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition is expected to enhance Zoetis' presence in veterinary diagnostics, a category of the animal health industry with approximately 10% compound annual growth over the last three years .



WIRB-Copernicus Group, a Princeton-based medical research group, has opened a Tokyo office to expand its capabilities in conducting global clinical trials.  The company's Tokyo office will have a particular focus conducting trials for drug and diagnostic development for oncology and central nervous system diseases. WCG said the opening of the office helps alleviate some of the difficulties in rounding up appropriate sub populations for clinical trials.



Catalent Pharma Solutions and  Valerius Biopharma AG announced they are collaborating to develop and manufacture Valerius' biosimilar products.  Catalent is a Somerset-based provider of delivery technologies and development solutions for the health industry, and Valerius Biopharma is a Swiss biopharmaceutical company focused on treatment options for orphan and non-orphan biologics.



Visikol, a drug discovery and bio-imaging service provider, has relocated its entire operations to Whitehouse Station.  The new facility, located at the Salem One Technology Complex, will have offices, laboratory and manufacturing spaces. It will quadruple the company's physical footprint and will be a major factor in its growth and expansion plans.



People in the News



Bridgewater-based BioNJ Member Eli Lilly and Company announced that Sue Mahony, Ph.D., Senior Vice President of Lilly and President of Lilly Oncology, will retire at the end of August after 18 years of service with the company. Dr. Mahony led Lilly Oncology through the integration of ImClone, successfully launched several key brands -- including Verzenio™ -- and most recently led the refocusing of the company's oncology R&D strategy.



Piscataway-based BioNJ Member Adello Biologics announced that Chintu Patel has been named Chief Executive Officer of Adello Biologics, LLC., succeeding Peter Moesta, who is stepping down to pursue other opportunities. Most recently Co-Chief Executive Officer, Co-Chairman and Co-Founder of Amneal Pharmaceuticals, Mr. Patel is now a Co-Chairman of the Amneal Board of Directors. His vision of building a pharmaceutical company based upon quality and integrity led to Amneal's founding.



Lawrence Township-based BioNJ Member Adare, which specializes in producing medications to treat gastrointestinal disorders, has hired Robert Rush as Chief Financial Officer, Ajay Damani as Business Unit Leader of Pharmaceutical Technologies and Giuseppe Di Vincenzo as Vice President of Strategy-Princeton. 



Dial BioSciences, the environmental services unit of Roseland-based Dial Environmental, has added two C-suite executives as it prepares to grow its presence in the market.  The company said that Philip D. Clark was hired as Executive Vice President and Chief Sales Officer, while Robert G. Petoia was hired as Chief Financial Officer. Dial BioSciences uses biomaterials originally developed for medical device implants to eliminate mold at business and home sites.

Institution and Education News




Rutgers University-New Brunswick engineers have created a 3D-printed smart gel that walks underwater and grabs objects and moves them.  The watery creation could lead to soft robots that mimic sea animals like the octopus, which can walk underwater and bump into things without damaging them. It may also lead to artificial heart, stomach and other muscles, along with devices for diagnosing diseases, detecting and delivering drugs and performing underwater inspections.



Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, announced that it and Rutgers University have been awarded a five-year, $5.5 million partnership grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.



Rutgers University has been awarded three  National Science Foundation grants totaling more than $470,000.  U.S. Rep. Frank Pallone Jr., D-6 th  District, said the grants will support innovative science projects. Grants include: $185,000 for a project called Ancient Solutions and Singularity Analysis in Geometric Flows, $105,552 for a project called Discrete Conformal Geometry of Surfaces and Applications and $179,997 for a project called Uncertainty Quantification in High-Dimensional Structured Regression Problems.



The Howard Hughes Medical Institute has named Cliff Brangwynne, Associate Professor of Chemical and Biological Engineering, as one of 19 new HHMI Investigators. This designation, one of the most coveted honors in biomedical science, provides seven years of funding. This brings to four the number of HHMI investigators at Princeton, the others being Bonnie Bassler, Carlos Brody and Eric Wieschaus.

Funding News



With support from the New Jersey Economic Development Authority (EDA), medical device maker Nephros, Inc. has developed and commercialized water-filtration systems designed to decrease the incidence of infectious diseases in hospitals and dialysis clinics. More than 500 facilities in the United States currently use the South Orange-based company's innovative technology.

Special Programs from Our Partners for BioNJ Members


BIO International Convention
Visit the NJ Pavilion -- Booth #1712!
June 4-7, 2018 | Boston

The BIO International Convention is back in Boston, June 4-7, to celebrate history-making innovation. Join us to take advantage of unparalleled business partnering, gain insights from thought leaders in hundreds of education sessions and network with 16,000+ of biotech's most influential. Register now at convention.bio.org . Plus, kick off the first full day at BIO 2018 with an engaging and inspiring conversation with Robin Roberts, Co-Anchor, ABC News' Good Morning America, Best-Selling Author, and Cancer Survivor. 

Stop by the Québec Pavilion, # 770, to discuss potential collaborations. Click here to schedule a meeting. 


June 5, 2018 | Boston

Endpoints News  editor John Carroll is bringing together some of the world's top authorities on designing and executing an R&D strategy that will deliver the maximum return on investment. After falling steadily over the past decade, there's an unprecedented push to create a profitable and sustainable strategy for developing new drugs and finally delivering a boost on ROI. What have the top players done right, and where have they gone wrong? What role will AI and other new technologies play in improving R&D efficiency? And how will these ideas influence the work now underway at your biotech company? This is a discussion that centers on the biggest issues now confronting the $160 billion drug R&D industry. And you won't want to miss out.


Sponsored by BioNJ
June 26-28, 2018 | Jersey City

The Precision Medicine Leaders' Summit has firmly established itself as the definitive thought leadership  event within this burgeoning sphere. After two successful years in San Diego, we are bringing  the conference to the friendly confines of Jersey City. With close proximity to numerous biopharma  companies, academic institutions, leading medical centers and Wall Street, the 2018 event promises to  engage a diverse group of participants. Join us and learn from the many forward-thinking speakers and  play an integral part in the narrative through interactive roundtables and networking opportunities.  With a format weighted towards panel discussions, coupled with lengthy Q&A, it aims to be the  highlight in the 2018 Precision Medicine calendar. 


July 10-11, 2018 | New York City

Come meet, interact and network with more than 500 VCs, Corporate VCs, angel investors, investment bankers and CEOs of early stage and emerging growth companies on the Life Sciences Track at the prestigious  New York Venture Summit .  Whether you're a healthcare start - up seeking capital and exposure, or a medtech investor seeking new deals, the New York Venture Summit presented by youngStartup Ventures -- is the event you won't want to miss. The summit will feature more than 100 VCs on interactive panels; presentations from more than 50 top innovators and high-level networking opportunities. BioNJ has made special arrangement for our Members to receive a special discount of 10% off the existing "early bird" rates.  Click here to register. Email [email protected] for the BioNJ discount code.
 
Call for Top Innovators: A select group of  more than 50 Top Innovators from the life sciences/healthcare, as well as technology, CleanTech and Edtech sectors will be chosen to present their breakthrough investment opportunities.  For more information or to be considered for one of the Top Innovator slots click here .


July 17-18, 2018 | Bedminster

The 14th annual Public Relations & Communications Summit, taking place on July 17­-18 at Mallinckrodt's Bedminster, NJ offices, is designed to help life sciences communicators push boundaries and move outside of your comfort zone to better position the industry, your company, your brands and yourself. This is the only meeting place exclusively designed for life sciences communicators, and it provides you with the content and networking you need to improve your communications strategy and expand your professional network. Learn more about the conference and its attendees here: https://goo.gl/RNFApx.


 
The MedTech Conference
September 24-26, 2018 | Philadelphia

The MedTech Conference is the leading North American gathering of global medtech executives. More than 2,700 attendees will network, gain access to capital and share insights in Philadelphia, PA. from September 24-26. The conference features world-class plenary speakers, networking and business development. BioNJ Members receive a 10% discount. Contact [email protected] for BioNJ's special discount code. Visit www.themedtechconference.com to learn more about the conference.